Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (DE:IKAP)
FRANKFURT:IKAP
RESEARCH TOOLSreports
Aurinia Pharmaceuticals (IKAP) Stock Price & Analysis
1 Followers
IKAP Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.36 - €11.20
Previous Close€4.65
Volume0.00
Average Volume (3M)2.50K
Market Cap
€687.26M
Enterprise Value€451.09M
Total Cash (Recent Filing)$350.49M
Total Debt (Recent Filing)$97.61M
Price to Earnings (P/E)N/A
Beta1.33
Next Earnings
May 02, 2024EPS Estimate
-€0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding144,617,762
10 Day Avg. Volume0
30 Day Avg. Volume2,500
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.97
Price to Sales (P/S)14.90
Price to Cash Flow (P/CF)12.90
P/FCF Ratio11.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.57
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda-5.84
Forecast
1Y Price Target
€10.11Price Target Upside120.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Aurinia Pharmaceuticals News
PremiumCompany Announcements
Aurinia Pharmaceuticals to Present at Investor ConferencePremiumCompany Announcements
Aurinia Pharmaceuticals Announces Q1 Results Date
PremiumCompany Announcements
Aurinia Pharma to Connect at Healthcare Investor Event
PremiumCompany Announcements
Aurinia Pharmaceuticals Announces Executive R&D Leadership Change
PremiumCompany Announcements
Aurinia Pharmaceuticals Launches Share Buyback PlanPremiumCompany Announcements
Aurinia Pharmaceuticals Engages Investors at March Conferences
Bulls Say, Bears Say
Bulls Say
Drug Approval And Sales GrowthLUPKYNIS has been approved in the U.S. and Europe, with high projections for peak sales and royalties, and a demonstrated strong momentum in its launch with successive positive quarters.
Financial OutlookAurinia is on the path to being cash flow-positive and likely GAAP profitable, with expectations of a 32.5% annual growth in net product revenues and solid guidance for the upcoming year's revenues.
Share Repurchase ProgramAurinia's share repurchase program reflects the Board's confidence in the company's growth prospects and is seen as accretive to shareholders, indicating potential value increase.
Bears Say
Market ChallengesLack of Acquirer Reflects Difficulty in Building LN Market
Product PipelineAUPH will discontinue future development of the early-stage pipeline (AUR200 and AUR300).
Stock PerformanceShares have dropped to a 52-week low following the conclusion of the strategic review without a transaction.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.18% Other Institutional Investors
99.82% Public Companies and
Individual Investors
IKAP FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was €4.36 and its highest was €11.20 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Currently, no data Available
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is May 02, 2024 which is in 6 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Feb 15, 2024. The company reported -€0.177 earnings per share for the quarter, missing the consensus estimate of -€0.152 by -€0.025.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is -€0.13.
How many shares outstanding does Aurinia Pharmaceuticals have?
Currently, no data Available
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of -€0.177 in its last earnings report, missing expectations of -€0.152. Following the earnings report the stock price went down -24.1%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:IKAP
---
Aurinia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.11 (120.74% Upside)
€10.11 (120.74% Upside)
Blogger Sentiment
Bullish
DE:IKAP Sentiment 92%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.20%
12-Months-Change
Fundamentals
Return on Equity
-19.92%
Trailing 12-Months
Asset Growth
16.40%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
IKAP Earnings Call
Q4 2024
0:00 / 0:00
---
IKAP Revenue Breakdown
90.33% Product revenue, net
9.67% License and contract revenue
---
IKAP Stock 12 Months Forecast
Average Price Target
€10.11
▲(120.74% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Xencor
―
Fate Therapeutics
―
Verastem
―
Aurinia Pharmaceuticals
―
Best Analysts Covering IKAP
1 Year
1 Year Success Rate
13/29 ratings generated profit
1 Year Average Return
+8.85%
reiterated a buy rating 2 months ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 44.83% of your transactions generating a profit, with an average return of +8.85% per trade.
---